However, these data support the use of EGFR TKIs as the standard-of-care first-line in the treatment of Asian patients with EGFR-mutated NSCLC [I, A] (Figure 3). A European analysis has reported a significant improvement in PFS and overall survival for patients receiving second-line chemotherapy compared with second-line EGFR TKI therapy in patients (n ¼ 1278) with pretreated NSCLC (PFS 4.3 versus 2.83 months, HR 0.66, 95% CI 0.57–0.77, OS 8.39 versus 4.99 months, HR 0.7, 95% CI 0.59–0.83; P < 0.0001).

In resected EGFR-mutant NSCLC patients, adjuvant EGFR-TKIs were significantly better than chemotherapy in terms of DFS (HR: 0.41; 95%CI: 0.24-0.70, P = 0.001)...

In the population with EGFR mutations, HR for DFS was 0.48 (95% CI, 0.36-0.65), corresponding to an absolute benefit of 9.5% at 3 years, with a reduced risk of distant metastasis (OR, 0.71; 95% CI, 0.56-0.92).

Our real-world data revealed that the swift and widespread utilization of newer-generation EGFR-TKIs in patients with EGFR mutation-positive non-small-cell lung cancer, and that these newer-generation EGFR-TKIs can prolong overall survival regardless of hospital volume or type.

Combined SRS and TKI resulted in favorable outcomes in EGFR-mutated NSCLC patients with newly diagnosed BMs.

From March 2013 to February 2019, completely resected stage I NSCLC (8th TNM staging) patients with sensitive EGFR mutation were included….For subgroup analyses, adjuvant EGFR-TKIs were associated with favorable 5-year DFS rates in both IA (100.0% vs. 84.5%; P = 0.007), and IB group (98.8% vs. 75.3%; P = 0.008).

Stage IV EGFRm mNSCLC adults that initiated 1L EGFR TKI (first, second, or third generation), IO ± chemotherapy (IO users), or chemotherapy alone from 5/2017–12/2019 were identified from the Flatiron database....Compared to IO and chemotherapy, EGFR TKIs had longer median TTNTD (EGFR TKI: 14.8 months, 95% CI: 13.5–16.3; IO: 3.7 months, 95% CI 2.8–6.2; chemotherapy: 4.4 months, 95% CI 3.1–6.8, p < 0.001).

Unresectable stage III and stage IV EGFR-mutated NSCLC patients were investigated....Patients received EGFR-TKI as the first-line treatment...patients showed a better median PFS (15 vs. 13 months; P=0.026) and a similar median OS (29 vs. 30 months; P=0.820) compared to stage IV patients. Stage IV was an independent prognostic factor for PFS [hazard ratio (HR)=1.47, 95% confidence interval (CI): 1.06-2.04; P=0.021]...

We examined the effects of minocycline on the outcomes of EGFR-mutant NSCLC treated with first-line EGFR-TKIs based on a single-center retrospective analysis....The treatment efficacy of first-line EGFR-TKIs was compared between patients who received minocycline and those who did not. Median progression-free survival (PFS) with first-line EGFR-TKIs was significantly longer in the minocycline group (N = 32) than in the control group (N = 106); 714 (95% confidence interval CI 411–1247) days vs. 420 (95% CI 343–626) days, p = 0.019.

It was a retrospective, single-arm real-world study and a total of 39 patients with stage ⅢB to Ⅳ EGFR mutant NSCLC….All patients received EGFR-TKIs synchronously combined with pemetrexed and platinum-containing chemotherapy for 4-6 cycles as first-line treatment, followed by EGFR-TKI monotherapy with or without pemetrexed maintenance therapy.... The ORR was 61.5% (24/39), the DCR was 94.9% (37/39) and the median PFS was 16.4 months (95%CI: 12.1-20.7 months).....EGFR-TKIs synchronously combined with chemotherapy followed by EGFR-TKI monotherapy with or without pemetrexed maintenance therapy has a certain therapeutic effect and fairly good safety, which can prolong PFS in patients with EGFR mutated advanced NSCLC.

This multicenter clinical trial was conducted in China from June 15, 2018 to May 31, 2019. A total of 92 NSCLC patients harboring EGFR sensitive mutations were included…patients received TKI combined with pemetrexed had a significantly longer PFS than patients received TKI monotherapy (p=0.013).

This study was retrospective, 177 advanced EGFR-mutant NSCLC patients...34 of 177 patients with T2DM were treated with EGFR TKI and metformin (group B)...The mean PFS among group A, B and C were 11.48, 17.75 and 5.51 months, respectively, p-value=0.003...This study demonstrated that concomitant use of EGFR TKI and metformin was associated with increased OS, and PFS in patients with advanced EGFR-mutant NSCLC and T2DM.

The EGFR-TKIs were administered to 63·9% (179/280) of EGFR mutated patients as first-line treatment. The overall median OS was 23·2 (95%CI 19·5-25·5) months, and patients treated at tier 1 cities had better OS than that of tier 2 cities. Also, the OS in patients with EGFR mutation was longer than those with EGFR wild type.

As shown in Fig. 3B, the effect of adjuvant EGFR-TKIs in resected NSCLC patients harboring EGFR mutations was further analyzed. The combined results indicated that adjuvant EGFR-TKIs could significantly increase DFS compared to control group in resected NSCLC patients harboring EGFR mutations (HR 0.46, 95% CI 0.29–0.72)....Adjuvant EGFR-TKIs therapy could significantly prolong DFS in patients with completely resected early-stage EGFR mutation-positive NSCLC, but had no impact on OS. Adjuvant EGFR-TKIs could be an important treatment option in patients with resected early-stage EGFR-mutant NSCLC.

Adjuvant EGFR TKIs significantly improved disease-free survival in EGFR-mutated resected NSCLC (HR: 0.41; 95% CI: 0.24-0.70) and in all subgroups….Adjuvant EGFR TKIs significantly improved disease-free survival and non-significantly improved overall survival in resected EGFR-mutated NSCLC.

A retrospective chart review was performed to identify consecutive patients who received EGFR-TKIs as first-line treatment for postoperative recurrence of non-small-cell lung cancer (NSCLC) harbouring EGFR gene mutations...The objective response and disease control rates were 53% and 92%, respectively.

Overall, median TTF, OS, and DoR with EGFR TKIs was 9.9, 24.4 and 10.0 mos, and ORR was 43%. Strongest responses were seen in pts with major uncommon and/or compound mutations….In a real-world setting, EGFR TKIs were the tx of choice in pts with uncommon EGFR mutations.

Between April 2008 and December 2015, we analyzed 78 elderly patients with advanced NSCLC harboring drug-sensitive EGFR mutations with first-line EGFR-TKI treatment at four Japanese institutions….Despite the fact that it was a retrospective analysis, even with EGFR-TKI rechallenge treatment the response rate was 23%, progression-free survival was 5.3 months, and overall survival was 14.4 months.

Real-world retrospective cohort study, including patients diagnosed, with EGFRm, locally advanced or metastatic NSCLC...Median TD was 9.9 (95% CI: 6.6-12.5) months, median PFS was 8.1 (95% CI: 6.6-10.6) months and median OS was 21.3 (95% CI: 12.6-37.3) months for those who received EGFR-TKI treatment (n=56). 45 patients interrupted 1L treatment due to death (n=12, 26.7%) or disease progression (n=33, 73.3%).

As a first-line treatment for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), first-generation EGFR-TKIs combined with chemotherapy or antiangiogenic therapy was associated with significant improvement in ORR, DCR, PFS and OS compared with monotherapy.

This retrospective analysis included 117 advanced NSCLC patients with EGFR mutation who underwent next-generation sequencing (NGS) prior to treatment….The median PFS was significantly longer in the combination group than in the EGFR-TKI monotherapy group (19.00 months [95% CI, 14.67-23.33] vs. 11.70 months [95% CI, 10.81-12.59], p < 0.001).

Data of the EGFR-mutant lung cancer patients were evaluated retrospectively....The patients received erlotinib (83.8%) or other EGFR inhibitors (16.2%) for treatment. Median overall survival was 30.8 (range 20.2-41.4) months. Overall response rate (complete or partial response) was 61.9%... real-life outcomes of the patients with EGFR-mutant metastatic non-small cell lung cancer.

Comparing with EGFR-TKIs monotherapy,the first-line PFS of EGFR-TKI plus chemotherapy group was longer, and the median PFS was 12.7 months VS 7.4 months (P = 0.018)....In advanced NSCLC patients with EGFR mutation and liver metastases, comparing with EGFR-TKIs monotherapy, taking EGFR-TKIs plus chemotherapy as first-line treatment had longer PFS...

The disease-free survival (DFS) and overall survival (OS) of patients with resected EGFR-mutant NSCLC after radical surgery treated with EGFR-TKIs versus non-EGFR-TKIs in the adjuvant setting were compared….EGFR-TKI treatment showed a significant beneficial effect on DFS (HR 0.42; 95% CI 0.31-0.57) and OS (HR 0.62; 95% CI 0.45-0.86) for patients with resected EGFR-mutant NSCLC after radical resection in the adjuvant setting.

The aim of this meta-analysis was to evaluate efficacy and toxicity of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in combination with chemotherapy (CT) compared to EGFR-TKI monotherapy as first-line treatment in advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutation....The ORR in the EGFR-TKI plus CT group was significantly higher than in the EGFR-TKI monotherapy group (RR = 1.18, 95% CI = 1.10-1.26).

EGFR TKIs were the preferred tx option in pts with NSCLC harboring uncommon EGFR mutations...Response was highest in pts with major uncommon, and/or compound mutations.

We conducted a multi-institutional retrospective analysis of patients with unresectable stage III EGFR-mutated NSCLC...CRT and EGFR TKI was associated with a significantly longer median PFS (26.1 months) compared to CRT and durvalumab or CRT alone (log-rank P=0.023).

A total of 75 patients with advanced NSCLC harboring sensitive EGFR mutations treated with afatinib, erlotinib, or gefitinib after EGFR-TKI treatment failure were retrospectively analyzed. Among them, 13 patients were treated with EGFR-TKI rechallenge immediately after the failure of PD-1 blockade therapy (experimental group) and the remaining 62 patients did not receive PD-1 inhibitor therapy before EGFR-TKI rechallenge (control group)....The objective response rates of EGFR-TKI rechallenge in the experimental and control groups were 46.1% and 16.1%, respectively, with a significant difference (p = 0.026).

EGFR-TKIs were used in 69 of 72 mutation positive patients….In EGFR mutation positive group, the disease control rate (DCR) was 95.8%, and the median progression-free survival (PFS) was 11 months. In EGFR mutation negative group, the DCR was 0%, and the median PFS was 1 month. The DCR and PFS were significantly different between the two groups (P<0.05).

Several generations of EGFR and ALK inhibitors have shown activity on brain metastases from EGFR and ALK mutant non-small-cell lung cancer.

For patients with activating EGFR mutations, the overall survival was longer in patients without RAS/PIK3CA/PTEN mutations (53.8 months vs. 27.4 months).

EGFR-TKIs combined with chemotherapy was effective in NSLCL patients with EGFR co-mutation with other oncogenic alterations and side-effects were tolerable.

One hundred and fourteen EGFR mutant patients treated with EGFR-TKI were followed until disease progression (PD)....The ORR was significantly higher for patients with EGFR as dominant clone according to plasma cfDNA NGS results (84.8% vs 60.9%, p = 0.016), and PFS was significantly longer (12 vs 8 months, HR = 2.58)…

The use of upfront EGFR-TKI with deferred RT at progression was associated with inferior OS in patients with EGFR-mutant unresectable LA-NSCLC.

This study focuses on a meta-analysis of therapeutic outcomes from phase II and III clinical trials for anti-EGFR monotherapy compared to anti-EGFR therapy in combination with targeted agents....A total of 34 studies were identified that fit the inclusion criteria from 2009-2019.….Sub-group analysis based on patient mutation status of wild-type (wt) EGFR, mutant EGFR, wt KRAS and mutant KRAS and a correlation analysis between OS, PFS and SPP was conducted....A statistically significant improvement in PFS was observed for anti-EGFR combination regimens compared to anti-EGFR monotherapy.

Among the 129 EGFR-positive patients who received EGFR-TKIs, the objective response rate was 56.6% and the median progression-free survival was 10.1 months (95% confidence interval: 9.0–11.2).

The purpose of this study was to examine the effectiveness of upfront thoracic radiotherapy in metastatic EGFR mutant NSCLC patients treated with chemotherapy or tyrosine kinase inhibitors (TKI)….Median overall survival (OS) was 26 months and progression free survival (PFS) (for first line treatment) was 10 months for the whole cohort, respectively....Survival advantage was also seen for patients group taking TKI at upfront setting (33 versus 23 months respectively, p=0.05).

Majority of patients were Caucasian (73%), diagnosed with stage IV (70%) adenocarcinoma (87%), and had a KRAS codon 12 mutation (78%). Twenty percent of patients were treated with immunotherapy. Median overall survival was 28 months in the cohort and patients who received immunotherapy were found to have better survival versus those who did not (33 vs. 22 months, P=0.31).

We aim to assess the efficacy and safety of EGFR-TKIs compared to other chemotherapeutics in EGFR-mutated NSCLC….The results showed that EGFR-TKI therapy had improved PFS with a hazard ratio (HR) of 0.40 (95% CI: 0.36-0.44, p<0.001) compared to standard chemotherapy.